C3 and age-related macular degeneration: Rare variants of C3, CFH, CFI, and C9 that have thus far been associated with AMD have been shown to play a role in either the complement pathway, to have an impact on the mutational load, or to hold the promise of putative future therapeutic targets [19, 58, 59, 63, 65].